🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rodrigo de Carvalho Santana

Universidade de Ribeirão Preto

ORCID: 0000-0002-5887-8663

Also affiliated with Clinics Hospital of Ribeirão Preto

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19”.

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

Annals of Internal Medicine(2023)10.7326/m22-3428

N/A

0.785DataRank · unranked

31 citations

Kara W Chew, Mark J Giganti, Carlee Moser, Mauricio Pinilla, David A. Wohl +76 more

SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients

Journal of Molecular Cell Biology(2022)10.1093/jmcb/mjac021

N/A

0DataRank · unranked

64 citations

Ítalo A. Castro, Ronaldo B. Martins, Leonardo La Serra, Flávio P. Veras, Daniele C. Nascimento +38 more

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102787

N/A

0DataRank · unranked

3 citations

Carlee Moser, Nikolaus Jilg, Justin Ritz, David A. Wohl, Jonathan Z. Li +89 more